Cheaper generics save UK's NHS GBP400M a year, study confirms

19 May 2009

In 2007 the UK's National Audit Office reported that Primary Care Trusts could save more than GBP200.0 million ($305.8 million) a year without  compromising patient care if general practitioners prescribed cheaper,  generic drugs. Keele University has now confirmed the NAO's finding by  calculating that almost GBP400.0 million has been saved by the Department  of Health, the National Health Service and PCTs in England, through more  cost-effective prescribing as recommended in the NAO report.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight